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Abstract The calcitonin (CT)-like (CL) receptor is a CT gene-
related peptide (CGRP) receptor or an adrenomedullin (AM)
receptor when co-expressed with receptor-activity-modifying
proteins (RAMP) 1 or 2, respectively. The CL receptor shows
57% overall sequence identity with the CT receptor, but the
homology is much lower in the extreme N-terminus. An N-ter-
minal deletion mutant of the human (h) CL receptor (v18-hCL)
and a chimeric receptor consisting of the N-terminal amino
acids of the porcine (p) CT receptor fused to the v18-hCL
receptor (pCT^hCL) were therefore analyzed. The v18-hCL
receptor function was abolished when co-expressed with
RAMP1 or -2. The pCT^hCL receptor was a fully functional
CGRP receptor when co-expressed with RAMP1, but the
RAMP2-dependent AM receptor function was impaired. Lim-
ited sequence similarities in the N-terminus of the pCT and the
hCL receptors rescue CGRP but not AM receptor binding and
signalling.
/ 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Calcitonin (CT), CT gene-related peptide (CGRP), adreno-
medullin (AM) and amylin are closely related hormones and
neuropeptides consisting of 32 to 52 amino acids [1]. They
have in common six or seven amino acid ring structures
formed by a disul¢de bridge near the N-terminus, an adjacent
alpha helix of up to 10 amino acids and amidated C-termini.
The similarity of the peptides is responsible for their cross-
reactivity with the receptors. Biological actions include hypo-
calcaemia (CT), vasodilatation (CGRP and AM) and inhibi-
tion of gastric emptying (amylin).
The CT receptor and the CT-like (CL) receptor are closely
related members of the B family of G protein coupled recep-
tors with putative seven transmembrane domains [2^4]. The
initially orphan CL receptor interacts with associated recep-
tor-activity-modifying proteins (RAMP) [5^7]. The RAMP
are proteins with an extracellular N-terminus of about 100
amino acids, a 20 amino acid single transmembrane domain
and an intracellular domain of up to 10 amino acids. When
co-expressed with RAMP1 the CL receptor recognized
CGRP. With RAMP2 or -3 an AM-speci¢c receptor was ob-
served. The CT receptor does not require any known RAMP
to bind CT, but CGRP was only recognized when the CT
receptor was co-expressed with RAMP1 [8]. CT and CL re-
ceptors form non-covalent heterodimeric complexes with the
RAMP at the plasma membrane which de¢ne ligand speci¢c-
ity for CGRP, AM or amylin [8^12].
The interactions between receptors and RAMP have been
investigated. As a result it was revealed that the Asn117 resi-
due in the CL receptor can only be substituted by an Asp.
Other substitutions in position 117 led to de¢cient or absent
recognition of CGRP by the CL receptor/RAMP1 complexes
[9].
In humans the CT and the CL receptors show an overall
amino acid sequence identity of 57%. But the extreme N-ter-
mini of the receptors up to the ¢rst conserved cysteine residue
show only limited similarity (Fig. 1). A naturally occurring
truncated human (h) CT receptor isotype, lacking the signal
sequence and the N-terminal 23 amino acids, has wild-type
CT receptor function [13]. Here, the extreme N-terminus of
the hCL receptor was therefore removed and examined as a
potential region de¢ning ligand speci¢city for CGRP or AM
when co-expressed with hRAMP1 and -2, respectively. The
corresponding deletion mutant of the hCL receptor (v18-
hCL) lost its function as a CGRP and AM receptor when
co-expressed with hRAMP1 or -2. Substitution of the ¢rst
18 amino acids of the hCL receptor by the corresponding
sequence of the porcine CT receptor (pCT^hCL) reconstituted
hRAMP1-dependent CGRP recognition, but the hRAMP2-
dependent AM response was impaired.
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2. Materials and methods
2.1. Materials
Human KCGRP was from Bachem (Bubendorf, Switzerland) and
hAM was from Peptide Institute (Osaka, Japan). Na[125I] and Hy-
bond ECL1 nitrocellulose membranes were from Amersham Interna-
tional (Little Chalfont, UK), and restriction enzymes were from
Promega (Madison, WI, USA) and Roche Diagnostics (Rotkreuz,
Switzerland). Tissue culture supplies, LipofectAMINE and OptiMEM
medium for transfections were from Invitrogen (Carlsbad, CA, USA).
Other reagents, unless otherwise indicated, were from Sigma (St.
Louis, MO, USA) and Merck (Darmstadt, Germany).
2.2. cDNA and mutagenesis
Expression constructs encoding hRAMP1- and hRAMP2-V5-His6
(hRAMP1 and hRAMP2) were obtained as previously described [8].
The DNA encoding a pCT^hCL fusion receptor with C-terminal myc
and His6 epitope tags was cloned into the mammalian expression
vector pcDNA3 as follows. The cDNA encoding the hCL receptor
was subcloned into the EcoRI restriction site of plasmid pIC19H
(Gene Bank accession no. VB0091) [4]. An EcoRV/HpaI restriction
fragment, containing the 5P-noncoding sequence and the sequences
encoding the signal peptide and the amino acids 1 to 107 of the
hCL receptor, was replaced by an EcoRV/HpaI DNA fragment en-
coding the Ile19 to Val107 sequence of the hCL receptor, ampli¢ed by
PCR. This construct was digested with the EcoRV restriction enzyme
and a DNA fragment encoding the signal peptide, and the amino
acids 1 to 24 of the pCT receptor in frame with the hCL receptor
sequence beginning with Ile19 was introduced. This fragment was also
obtained by PCR and had an EcoRV and an adjacent BamHI restric-
tion site at the 5P-end and a 3P blunt end. The pCT^hCL receptor
fusion gene was then digested with BamHI and HindIII restriction
enzymes. This removed a DNA fragment that encoded the pCT^
hCL fusion receptor lacking 187 amino acids at the C-terminus.
The fragment was cloned into BamHI/HindIII digested pcDNA3 en-
coding myc and His6 epitope tags downstream of the HindIII restric-
tion site. The resulting plasmid was digested with the HindIII restric-
tion enzyme and the missing 187 amino acids C-terminal portion of
the pCT^hCL receptor was introduced with a PCR-ampli¢ed DNA
fragment containing the corresponding coding sequence in between
HindIII restriction sites in frame with the upstream pCT^hCL recep-
tor and the downstream myc-His6 encoding sequences. The ¢nal
pCT^hCL-myc-His6 (pCT^hCL) receptor construct was veri¢ed by
sequencing.
The v18-hCL-myc-His6 receptor expression construct was derived
from pCT^hCL-myc-His6 receptor. pCT^hCL-myc-His6 receptor con-
struct was digested with BamHI, RcaI and HpaI restriction enzymes.
The RcaI/HpaI fragment encoding the Met20 to Asn139 domain of the
hCL receptor was isolated. A BamHI/RcaI DNA fragment encoding
the 24 amino acids signal sequence of the pCT receptor in frame with
the downstream hCL-myc-His6 receptor sequence from Met20 to
Asn139 was ampli¢ed with Pfu DNA Polymerase (Amersham Pharma-
cia Biotech, Little Chalfont, UK). The BamHI/RcaI and RcaI/HpaI
fragments isolated from pCT^hCL-myc-His6 receptor were cloned
into the BamHI/HpaI digested pCT^hCL-myc-His6, receptor revealing
v18-hCL-myc-His6 (v18-hCL) receptor. This construct was also veri-
¢ed by sequencing.
2.3. Cell culture, transfection and cAMP measurement
Chinese hamster ovary (CHO) cells were cultured in Ham F12
medium supplemented with 10% fetal calf serum. 24 or 48 h before
transient transfection 5.2 or 2.6U104 CHO cells per cm2 were seeded
into 24-well plates or 100-mm dishes, respectively. The cells were
transfected at 37‡C for 4 h in 130 Wl OptiMEM medium per cm2
containing 0.5 Wl LipofectAMINE and 105 ng DNA of indicated
receptor and hRAMP1- or hRAMP2-V5-His6 expression constructs.
In control experiments, 105 ng hRAMP1 or hRAMP2 expression
constructs were transfected together with 105 ng pcDNA3 to keep
the DNA concentration constant. The transfected cells were kept in
tissue culture medium for two days prior to the experiments. cAMP
was measured in extracts of cells as described [14].
2.4. Radioligand binding, cross-linking and protein gel autoradiography
Transiently transfected CHO cells in 100-mm dishes were detached
with 0.05% EDTA in PBS and collected by centrifugation at 200Ug
for 5 min. [125I]-labeled hKCGRP and -hAM (7.4 1013 Bq/mmol) were
prepared as described [15,16]. The cells were incubated with 100 kBq
[125I]hKCGRP or [125I]hAM in 0.4 ml HAM F12/DMEM mixture
(1:1), 0.1% BSA on ice for 2 h. Subsequently, the cells were washed
with PBS and incubated on ice for 1 h in 400 Wl PBS containing 1 mM
cross-linker BS3 (Pierce Biotechnology, Rockford, IL, USA). Cross-
linking was quenched by the addition of 1 M Tris^HCl (pH 8.0) to a
¢nal concentration of 50 mM. After centrifugation at 200Ug for 3 min
the cells were lysed in 300 Wl 50 mM HEPES (pH 7.5), 140 mM NaCl,
0.5% Triton X-100 (BioRad Laboratories, Hercules, CA, USA), 1 mM
phenylmethylsulfonyl £uoride, 3 Wg/ml aprotinin and 3 Wg/ml leupep-
tin (lysis bu¡er). The cell lysates were cleared by centrifugation at
20 000Ug for 5 min. Myc-tagged receptor components were immuno-
precipitated from the supernatants by sequential incubation at 4‡C
with 30 Wl ImmunoPure immobilized protein G (Pierce Biotechnol-
ogy) for 1 h to remove non-speci¢cally adsorbing proteins, 3 Wg myc
antibodies (Invitrogen) for 2 h, and with 45 Wl ImmunoPure immobi-
lized protein G overnight on an end-over-end rotator. The precipitates
were collected by centrifugation at 2700Ug for 3 min. The pellets
were washed once with lysis bu¡er. The amounts of [125I]-labeled
peptides in the immunoprecipitates were measured in a Q-counter
(Kontron, Zurich, Switzerland). Deglycosylation of proteins bound
to ImmunoPure immobilized protein G was carried out at 37‡C for
18 h with 2 U of N-glycosidase F (Roche Diagnostics) in 50 Wl lysis
bu¡er adjusted to 10 mM EDTA, 0.1% SDS, 0.5% octylglucopyrano-
side and 1% L-mercaptoethanol. The proteins were then eluted at
60‡C for 5 min from the ImmunoPure immobilized protein G and
the samples centrifuged at 10 000Ug for 3 min. Proteins in the super-
natant were subjected to 10% SDS^PAGE and electrotransferred to
nitrocellulose Hybond ECL membranes (BioRad Laboratories) in a
Trans-Blot cell (BioRad Laboratories) at 10 V and 4‡C overnight.
Cross-linked [125I]hKCGRP and -hAM were detected by autoradiog-
raphy with Hyper¢lm MP ¢lm (Amersham Pharmacia Biotech).
2.5. Immunostaining and confocal microscopy
CHO cells were detached with trypsin/EDTA 48 to 72 h after trans-
fection. Staining was performed at room temperature. The cells were
¢rst incubated with 50 Wg/ml TRITC^ConA (Molecular Probes, Eu-
gene, OR, USA) in PBS for 20 min, washed with PBS and ¢xed with
4% formalin in PBS for 20 min, washed again with PBS and incubated
with immunostaining medium (DMEM/Ham F12 (1:1), 0.1% BSA,
0.1% saponin) for 20 min. The cells were then incubated for 1 h in 200
Wl immunostaining medium with rabbit antiserum to myc (Cell Signal-
ing Technology, Beverley, MA, USA; 1:300) for receptor detection or
with mouse antibodies to V5 (Invitrogen; 1:300) for hRAMP2 detec-
tion. Subsequently, the cells were washed twice and then incubated
with Alexa488 anti-rabbit or Alexa488 anti-mouse antiserum (Molec-
ular Probes; 1:200) for 30 min. After three washes the cells were
collected by centrifugation and 5 Wl were dry-mounted with Immu-
Mount (Shandon, Pittsburgh, PA, USA). Confocal images were ob-
tained on a Leica TCS SP2 (Leica Microsystems, Heidelberg, Ger-
Fig. 1. Amino acid sequence alignment of the N-termini of wild-type and mutant hCL and pCT receptors. The sequences shown lack the puta-
tive signal peptides and include the ¢rst predicted N-glycosylation consensus site of the receptors (S). Conserved cysteines (*) and similar (gray
boxed) and identical (black boxed) amino acids are indicated. A conserved K/R-X-K/R motif found in mammalian CL and CT receptors is
underlined.
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many) (U63 1.32 N.A. HCX PL APO objective) by simultaneous
excitation with an extended argon ion laser at 488 nm for the
Alexa488 and an internal He/Ne laser at 543 nm for TRITC.
2.6. Statistical analysis
The values for half-maximal e¡ective concentrations (EC50) were
calculated by sigmoidal regression analysis using Prism 3.0 (GraphPad
Software, San Diego, CA, USA). The results are meansRS.E.M. Dif-
ferences between mean values were analyzed by ANOVA. P values
6 0.05 were considered statistically signi¢cant.
3. Results
3.1. Deletion of the 18 N-terminal amino acids of the hCL
receptor results in loss of [125I]hKCGRP and -hAM
binding and signalling
Binding and chemical cross-linking of [125I]hKCGRP and
-hAM to corresponding receptors was carried out in CHO
cells co-expressing the hCL or the mutant receptors together
with hRAMP1 or -2 (Fig. 2). In cells co-transfected with the
hCL receptor and the hRAMP1 expression construct,
[125I]hK-CGRP was cross-linked in equal amounts to two pro-
tein components that, after deglycosylation, had apparent mo-
lecular weights of 50 and 65 kDa. They di¡ered in size by the
molecular weight calculated for hRAMP1. Both [125I]hK-
CGRP-binding proteins remained undetectable in cells ex-
pressing hRAMP1 alone or hRAMP1 together with the
v18-hCL receptor. In cells expressing the hCL receptor to-
gether with hRAMP2 a predominant [125I]hAM cross-linked
protein component had a size similar to the 50-kDa [125I]hK-
CGRP-binding protein in hCL receptor/hRAMP1 co-express-
ing cells. A minor [125I]hAM cross-linking product was
slightly larger than the 65-kDa [125I]hKCGRP-binding protein
in hCL receptor/hRAMP1 expressing cells. [125I]hAM cross-
linked proteins were undetectable in cells expressing hRAMP2
alone or together with the v18-hCL receptor.
In CHO cells transfected with the hCL or the v18-hCL
receptor together with hRAMP1 or -2 mean basal cAMP
levels ranged from 2.3 to 3.2 pmol/well (Ps 0.05). In cells
co-expressing the hCL receptor and hRAMP1 hKCGRP max-
imally stimulated cAMP formation 45R10-fold with an EC50
of 1.1 R 0.4 nM (n=4; Fig. 3, top panel). In v18-hCL receptor
and hRAMP1 co-expressing cells hKCGRP was about 1000-
fold less potent and maximal cAMP levels were not obtained
Fig. 2. Chemical cross-linking of [125I]hKCGRP and -hAM to corre-
sponding binding proteins. CHO cells were transfected with
hRAMP1 (left panels) or hRAMP2 (right panels) expression con-
structs together with pcDNA3 or the indicated receptor expression
constructs. Radioligand binding and cross-linking with BS3, and im-
munoprecipitation of myc-tagged receptors with corresponding anti-
bodies and subsequent deglycosylation was carried out as described
in Section 2. Immunoextracts were subjected to 10% SDS^PAGE
and radioligand cross-linking products were visualized by autora-
diography (top panels). The amount of [125I]hKCGRP and -hAM
co-immunoprecipitated with the myc-tagged receptors after cross-
linking were measured in a Q-counter and re£ected radioligand bind-
ing (bottom panels). [125I]hKCGRP and -hAM in immunoextracts of
cells transfected with hRAMP1 or -2 expression constructs together
with pcDNA3 was considered as non-speci¢cally bound. Binding of
[125I]hKCGRP (4.7R 0.9 kBq/dish (n=5)) and of [125I]hAM (3.4 R
1.6 kBq/dish (n=4)) to hCL receptor/hRAMP1 and -2 expressing
cells, respectively, was set to 100%.
Fig. 3. Stimulation of cAMP production. CHO cells were trans-
fected with hCL (b), pCT^hCL (F) or v18-hCL (R) receptor to-
gether with hRAMP1 (top panel) or hRAMP2 (bottom panel) and
stimulated with indicated concentrations of hKCGRP (top panel) or
hAM (bottom panel). Results are meansRS.E.M. of four experi-
ments.
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with up to 1 WM hKCGRP. In CHO-cells co-expressing the
hCL receptor and hRAMP2 hAM stimulated cAMP forma-
tion 20R 7-fold with an EC50 of 2.4 R 1.3 nM (n=4; Fig. 3,
bottom panel). In v18-hCL receptor and hRAMP2 co-ex-
pressing CHO-cells, on the other hand, 1 WM hAM only min-
imally stimulated cAMP formation. Taken together, trunca-
tion of the N-terminus of the hCL receptor by 18 amino acids
impairs hRAMP1-dependent CGRP receptor function and
abolishes hRAMP2-assisted hAM receptor activity.
3.2. Substitution of the 18 N-terminal amino acids of the hCL
receptor by the corresponding N-terminal sequence of the
pCT receptor maintains the CGRP receptor function, but
impairs the interaction with hAM
In CHO cells co-expressing the chimeric pCT^hCL receptor
with hRAMP1 [125I]hKCGRP binding and cross-linking to 50
and 65-kDa protein components was 150% of that in cells
expressing the hCL receptor together with hRAMP1 (Fig.
2). The small increase in size of the [125I]hKCGRP cross-link-
ing products in pCT^hCL receptor/hRAMP1 as compared to
hCL receptor/hRAMP1 expressing cells was likely caused by
the 6 amino acid longer N-terminus of the pCT^hCL receptor
as compared to the hCL receptor. But the size di¡erence was
comparable to that of [125I]hKCGRP cross-linking products in
the hCL receptor and hRAMP1 co-expressing cells and cor-
responded to the calculated molecular weight of hRAMP1.
[125I]hAM receptor cross-linking was not observed in CHO
cells expressing the pCT^hCL receptor together with
hRAMP2. Altogether, the results indicate the importance of
the 18 N-terminal amino acids of the hCL receptor for the
hRAMP2-dependent [125I]hAM binding.
In CHO cells co-transfected with the pCT^hCL receptor
and hRAMP1 or -2 expression constructs, mean basal
cAMP levels ranged from 3.2 to 3.9 pmol/well (Ps 0.05). In
cells expressing the pCT^hCL receptor together with
hRAMP1 the maximal cAMP response to hKCGRP was
38R 11-fold with an EC50 of 0.5 R 0.2 nM (n=4), comparable
to that in hCL receptor/hRAMP1 co-expressing cells (Fig. 3).
A maximal 33R 22-fold stimulation of cAMP formation by
hAM was observed in cells co-expressing the pCT^hCL recep-
tor and hRAMP2, but the EC50 increased to 43R 14 nM
(n=4) as compared to 2.4 R 1.3 nM (n=4) in hCL receptor/
hRAMP2 expressing cells (P6 0.05). Taken together, the
CGRP receptor function of the pCT^hCL receptor co-ex-
pressed with hRAMP1 was that of the hCL receptor, but
the 18 N-terminal amino acids of the hCL receptor were es-
sential for the hRAMP2-dependent high a⁄nity interaction
with hAM.
3.3. Cell surface expression of receptor constructs and
hRAMP2
The v18-hCL receptor co-transfected with hRAMP2 was
expressed at the cell surface as revealed by co-localization
with cell surface glycoproteins labeled with TRITC-ConA
(Fig. 4). The pattern of co-localization (yellow) was indistin-
guishable from that of the hCL and pCT^hCL receptors co-
transfected with hRAMP2. Similarly, hRAMP2 was expressed
at the cell surface when co-expressed with the hCL, pCT^hCL
and v18-hCL receptors. Thus, the impaired and lost function
of pCT^hCL and v18-hCL receptors together with hRAMP2
with respect to [125I]AM binding were not caused by defective
cell surface delivery of the mutated receptors and hRAMP2.
4. Discussion
The CL receptor requires RAMP1 or -2 for the recognition
of CGRP and AM, respectively [5]. The closely related CT
receptor recognizes CT without co-expressed RAMP, but
RAMP1 is required for the binding of CGRP [8]. The overall
homology of the amino acid sequences of the CL and CT
receptors is 57%. But the N-terminal regions of the CL and
the CT receptors di¡er widely. An N-terminal truncated CT
receptor still recognized CT [13]. Here we have investigated
the importance of the extreme N-terminus of the hCL recep-
tor for the interaction with CGRP or AM.
N-terminal truncation of the hCL receptor by 18 amino
acids as shown here abolished hKCGRP and hAM binding
and impaired stimulation of cAMP formation. With hKCGRP
the EC50 was increased by two orders of magnitude compared
to the intact hCL receptor and hRAMP1. Near maximal
cAMP levels were obtained at high concentrations. The inter-
Fig. 4. Immunochemical localization of receptors and hRAMP2. CHO cells were transfected with hCL (left panels), pCT^hCL (middle panels)
or v18-hCL (right panels) receptors together with hRAMP2. The cells were detached and surface glycoproteins stained with TRITC-ConA
(red), ¢xed, permeabilized and incubated with rabbit anti-myc antibodies for receptor recognition (upper panels) or with mouse anti-V5 anti-
bodies for RAMP2 recognition (lower panels). Staining was carried out with Alexa488-labeled anti-rabbit or anti-mouse antibodies (green), and
images were obtained by confocal laser scanning microscopy. The overlay of two out of six cells of two independent experiments is shown.
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action of hKCGRP with v18-hCL receptor/hRAMP1 rather
than their expression was impaired. With hAM marginal
cAMP stimulation was obtained at 1 WM as compared to
0.1 nM with the intact hCL receptor and hRAMP2. hAM
was therefore four orders of magnitude less potent. Nonethe-
less, expression of the hCL and the v18-hCL receptor and
hRAMP2 at the plasma membrane was comparable, as re-
vealed by co-localization with membrane glycoproteins exam-
ined by confocal scanning laser microscopy.
With the chimeric pCT^hCL receptor together with
hRAMP1 a fully functional CGRP receptor was obtained.
But in the presence of hRAMP2, hAM was two orders of
magnitude less potent at the pCT^hCL receptor as compared
to the wild-type hCL receptor.
The apparent molecular weights of [125I]hKCGRP cross-
linking products in hCL and pCT^hCL receptor/hRAMP1
expressing cells and their di¡erences in size were consistent
with deglycosylated [125I]hKCGRP/hCL receptor, -/hCL re-
ceptor/hRAMP1, -/pCT^hCL receptor and -/pCT^hCL recep-
tor/hRAMP1 complexes cross-linked at the cell surface. Sim-
ilarly, in hCL receptor and hRAMP2 co-expressing cells,
[125I]hAM/hCL receptor and -/hCL receptor/hRAMP2 com-
plexes were recognized, but cross-linking of the latter ap-
peared to occur with low e⁄ciency.
A dibasic K/R-X-K/R motif adjacent to the N-terminus of
the v18-CL receptor is the only common determinant of the
extreme N-terminus in the CL and CT receptors. This motif
may therefore be important for the recognition of CGRP by
the CL receptor/RAMP1 complex. This also applies for the
CL receptor/RAMP2 complex, but additional amino acids
near the N-terminus of the CL receptor are important for
AM receptor function.
Taken together, the 18 N-terminal amino acids of the hCL
receptor are required for the recognition of CGRP and AM.
Substitution of this extreme N-terminus of the hCL receptor
by the N-terminal 24 amino acids of the pCT receptor recon-
stituted the CGRP receptor. Amino acids in the extreme
N-terminus of the hCL receptor are essential for full recog-
nition of hAM.
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